James Chih-Hsin Yang, MD, PhD, is currently the Director of National Taiwan University Cancer Center Hospital since 2020. He received his MD from National Taiwan University (NTU) in 1986 and PhD degree at the Graduate Institute of Clinical Medicine, NTU. He completed his internal medicine residency at the NTU Hospital and medical oncology training between 1992 and 1995 at the National Cancer Institute at Bethesda, Maryland. He started his research and clinical staff career in NTU Hospital since 1995. He is the distinguished chair professor of Graduate Institute of Oncology at NTU. He is currently the President of Taiwan Association for the Study of Lung Cancer.

Dr Yang is a leader in lung cancer new drug development in the world and contributed to many new drug approval and translational research in lung cancer. He directly contributed to the development and approval of targeted therapies such as gefitinib, afatinib, osimertinib, aumolertinib, alectinib, brigatinib, crizotinib, tepotinib etc and participated development of most other cancer agents for treatment of lung cancer. He is the first to establish treatment for uncommon EGFR mutations and EGFR mutant patients with leptomeningeal metastasis. He has published more than 350 papers in peer-reviewed journals and was the Highly Cited Researcher of Clarivate database from 2019-2023. He served as associate editor of Journal of Thoracic Oncology. He received many domestic and international award and is the recipient of IASLC Sr. Paul A. Bunn Scientific Award from International Association for the Study of Lung Cancer in 2022.